한글목차

개요

세계의 성조숙증 치료 시장은 2023년에 17억 달러에 달하며, 2024-2031년의 예측 기간 중 CAGR 7.6%로 성장하며, 2031년에는 31억 달러에 달할 것으로 예측되고 있습니다.

조발성 사춘기란 소아에서 사춘기가 일찍 시작되는 것을 말하며, 남자아이의 경우 9세, 여자아이의 경우 8세 이전에 2차 성징이 나타나는 것이 특징입니다.

증상은 환자의 성별에 따라 다르며, 여아의 경우 유방 발달, 월경, 빠른 성장 등이, 남아의 경우 고환과 음경 비대, 목소리 깊어짐 등이 나타날 수 있습니다. 또한 다른 흔한 증상으로는 뼈의 성장으로 인해 성인의 키가 작아질 수 있습니다.

시장 역학 :

촉진요인

연구개발 및 제품 승인 증가

세계 성조숙증 치료 시장은 최근 다양한 연구개발로 인해 큰 성장세를 보이고 있습니다. 조발성 사춘기는 일반적으로 병력, 임상 소견, 영상 소견을 바탕으로 진단됩니다. 또한 조기 사춘기 발병을 치료하기 위한 첨단 연구개발이 이 시장의 성장을 가속하고 있습니다.

스프링거 저널에 따르면 2022년 1월 발표된 'Effect of gonadotropin-releasing hormone agonist agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty(성선자극호르몬 방출 호르몬 작용제 단독요법과 성장호르몬 병용요법이 최종 성인 키에 미치는 영향)'라는 제목의 논문에 따르면 성선자극호르몬 방출 호르몬 작용제 단독요법과 성장호르몬 병용요법(GnRHa)에 따르면 GnRHa는 남녀 모두 CPP의 표준 치료법입니다. 성호르몬 분비를 억제하여 사춘기를 지연시키고 급격한 골유합을 억제하여 최종 성인 신장을 성장호르몬의 범위 내로 조절하는 것으로 알려져 있습니다.

또한 업계 주요 기업은 이 시장 성장의 원동력이 될 수 있는 혁신적인 의약품을 출시했습니다. 예를 들어 BDR Pharmaceuticals는 2022년 2월 전립선암 환자를 위해 'BDENZA'라는 브랜드로 160mg의 'ENZALUTAMIDE'를 출시했습니다. 이 약은 지금까지 40mg과 80mg의 두 가지 유형이 있었고, 환자는 승인된 용량에 따라 하루에 두 알을 복용해야 했습니다.

억제요인

고가의 치료비, 약물 치료에 따른 부작용, 사람들의 인식 부족, 엄격한 규제 당국의 승인 등의 요인이 시장을 저해할 것으로 예상됩니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 촉진요인
    • 연구개발과 제품 인가의 증가
    • 호르몬 질환의 증가
  • 억제요인
    • 높은 치료비
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 미충족 요구
• 규제 분석

제6장 유형별

• 중추성 성조숙증
• 말초성 성조숙증

제7장 치료별

• 약물 요법
  • Leuprolide Acetate
  • Triptorelin
  • Histrelin Acetate
  • Nafarelin
  • 기타
• 수술
• 기타

제8장 최종사용자별

• 병원·클리닉
• 외래 수술 센터
• 재택의료
• 기타

제9장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제10장 경쟁 구도

• 경쟁 시나리오
• 제품 벤치마킹
• 기업 점유율 분석
• 주요 발전과 전략

제11장 기업 개요

• Pfizer Inc.
  • 회사 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Bachem A.G
• Aspen API
• Sanofi S.A
• Piramal Solutions
• Anygen Co. Ltd
• Sigma Aldrich
• Ferring Pharmaceuticals
• LGM Pharma
• AmbioPharm

제12장 부록

영문목차

Overview

The global precocious puberty treatment market reached US$ 1.7 billion in 2023 and is expected to reach US$ 3.1 billion by 2031 growing with a CAGR of 7.6% during the forecast period 2024-2031.

Precocious puberty is defined as the premature onset of puberty in children, characterized by the development of secondary sexual characteristics before the age of 9 in boys and 8 in girls.

The symptoms vary depending on the patient's gender, girls may experience breast development, menstruation, and rapid growth, while boys might show enlarged testicles and penis, facial hair expansion, and a deepening voice. Additionally, other common indications include bone growth, which might also lead to shorter adult height.

Market Dynamics: Drivers

Increasing Research & Development and Product Approvals

The global precocious puberty treatment market has witnessed significant growth due to various recent research and developments. Precocious puberty is usually diagnosed based on medical history and clinical and imaging findings. Also, advanced research and developments in treating precocious puberty drive this market growth.

According to Springer Journal, an article entitled Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty published in January 2022 states that GnRHa is a standard treatment for CPP in both boys and girls. It is known to suppress the secretion of sex hormones to slow puberty and suppress rapid bone fusion to achieve final adult height within the growth hormone range.

Moreover, key players in the industry launched innovative drugs that would drive this market growth. For instance, in February 2022, BDR Pharmaceuticals launched its brand ENZALUTAMIDE in 160mg with the brand name BDENZA for Prostate Cancer patients. This medicine was previously available in 40mg and 80mg strength for which patients had to consume two tablets a day as per approved dosage.

Restraints

Factors such as the high cost of the treatment, side effects associated with the treatment of drugs, lack of awareness among people, and stringent regulatory approvals, are expected to hamper the market.

Segment Analysis

The global precocious puberty treatment market is segmented based on type, treatment, end-user, and region.

The medications segment accounted for approximately 55.3% of the global precocious puberty treatment market share

The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of drugs globally have contributed to the growing demand for precocious puberty treatment.

According to clinicalTrials.gov, in August. 2023, Foresee Pharmaceuticals Co., Ltd. In collaboration with GeneScience Pharmaceuticals Co., Ltd. conducted a clinical trial to evaluate the efficacy, safety, and pharmacokinetics of leuprolide mesylate in subjects with Central Precocious Puberty.

Moreover, key players' ongoing research studies in the treatment of precocious puberty and launching new drugs would drive this market growth. For instance, in March 2023, Takeda Pharmaceuticals conducted an interventional study of Leuprolide Acetate Depot in children with central precocious puberty. The main aim is to check how leuprolide works to treat central precocious puberty in children.

Also, in March 2022, Accord BioPharma announced the U.S. launch of CAMCEVI (Leuprolide) injection emulsion for the treatment of advanced prostate cancer in adults.

Geographical Analysis

North America accounted for approximately 43.2% of the global precocious puberty market share

North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of precocious puberty, advancements in medical research & technology would drive this market growth.

According to a study published in the Journal of Clinical Endocrinology & Metabolism, in May 2023, the incidence of central precocious puberty in North America has been steadily increasing, with a prevalence of approximately 1 in 5,000 to 1 in 10,000 children. It is estimated that approximately 80% - 90% of CPP cases are idiopathic, especially in females, with a female-to-male ratio of around 20: 1.

Moreover, major key players' presence, well-advanced healthcare system, growing healthcare expenditure, and government support & funding in the development of drugs propel this market growth. For instance, in October 2023, Foresee Pharmaceuticals announced the first patient dosed in the Caspian, phase 3 clinical trial of leuprolide (fp-001) injectable emulsion, 42 mg for the treatment of central precocious puberty patients.

Market Segmentation

By Type

• Central Precocious Puberty
• Peripheral Precocious Puberty

By Treatment

• Medications
  • Leuprolide Acetate
  • Triptorelin
  • Histrelin Acetate
  • Nafarelin
  • Others
• Surgery
• Others

By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the precocious puberty treatment market include Pfizer Inc., Bachem A.G, Aspen API, Sanofi S.A, Piramal Solutions, Anygen Co. Ltd, Sigma Aldrich, Ferring Pharmaceuticals, LGM Pharma, and AmbioPharm among others.

Key Developments

• In April 2024, Foresee Pharmaceuticals Receives a Positive Recommendation from DSMB to Continue the Caspian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty.
• In January 2024, BDR Pharmaceuticals launches BDENZA a prostate cancer drug in oral solution form. The formulation provides an effective dosage form, with fewer side effects in comparison to existing oral dosage forms of enzalutamide.

Why Purchase the Report?

• To visualize the global precocious puberty treatment market segmentation based on type, treatment, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global precocious puberty treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global precocious puberty treatment market report would provide approximately 62 tables, 57 figures, and 181 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Research & Development and Product Approvals
    • 4.1.1.2. Growing Prevalence of Hormonal Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of the Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Central Precocious Puberty
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Peripheral Precocious Puberty

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Medications
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.2.1. Leuprolide Acetate
    • 7.2.2.2. Triptorelin
    • 7.2.2.3. Histrelin Acetate
    • 7.2.2.4. Nafarelin
    • 7.2.2.5. Others
• 7.3. Surgery
• 7.4. Others

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 8.1.2. Market Attractiveness Index, By End-user
• 8.2. Hospitals & Clinics
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ambulatory Surgical Centers
• 8.4. Home Care
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Product Benchmarking
• 10.3. Company Share Analysis
• 10.4. Key Developments and Strategies

11. Company Profiles

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Bachem A.G
• 11.3. Aspen API
• 11.4. Sanofi S.A
• 11.5. Piramal Solutions
• 11.6. Anygen Co. Ltd
• 11.7. Sigma Aldrich
• 11.8. Ferring Pharmaceuticals
• 11.9. LGM Pharma
• 11.10. AmbioPharm

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us